Circulating cf-miRNA as a more appropriate surrogate liquid biopsy marker than cfDNA for ovarian cancer

Ovarian cancer (OC) is an aggressive disease, primarily diagnosed in late stages with only 20% of patients surviving more than 5 years. Liquid biopsy markers have great potential to improve current diagnostic and prognostic methods. Here, we compared miRNAs and DNA methylation in matched plasma, wh...

Full description

Saved in:
Bibliographic Details
Main Authors: Gahlawat, Aoife Ward (Author) , Witte, Tania (Author) , Sinn, Peter (Author) , Schott, Sarah (Author)
Format: Article (Journal)
Language:English
Published: 04 April 2023
In: Scientific reports
Year: 2023, Volume: 13, Pages: 1-9
ISSN:2045-2322
DOI:10.1038/s41598-023-32243-x
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41598-023-32243-x
Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41598-023-32243-x
Get full text
Author Notes:Aoife Ward Gahlawat, Tania Witte, Peter Sinn & Sarah Schott
Description
Summary:Ovarian cancer (OC) is an aggressive disease, primarily diagnosed in late stages with only 20% of patients surviving more than 5 years. Liquid biopsy markers have great potential to improve current diagnostic and prognostic methods. Here, we compared miRNAs and DNA methylation in matched plasma, whole blood and tissues as a surrogate marker for OC. We found that while both cfDNA and cf-miRNAs levels were upregulated in OC compared to patients with benign lesions or healthy controls, only cf-miRNA levels were an independent prognosticator of survival. Following on our previous work, we found members of the miR-200 family, miR-200c and miR-141 to be upregulated in both plasma and matched tissues of OC patients which correlated with adverse clinical features. We could also show that the upregulation of miR-200c and -141 correlated with promoter DNA hypomethylation in tissues, but not in plasma or matched whole blood samples. As cf-miRNAs are more easily obtained and very stable in blood, we conclude that they might serve as a more appropriate surrogate liquid biopsy marker than cfDNA for OC.
Item Description:Gesehen am 19.06.2023
Physical Description:Online Resource
ISSN:2045-2322
DOI:10.1038/s41598-023-32243-x